Esperion Therapeutics

Aging Population And Precision Medicine Will Expand Cardiovascular Care

AnalystHighTarget

Not Invested

Consensus Narrative from 7 Analysts

Published

26 Aug 25

Updated

26 Aug 25

AnalystHighTarget's Fair Value

US$14.68

84.9% undervalued

26 Aug

US$2.21

26.3%

3.8%

26.3%

3.8%

Author's Valuation

US$14.7

84.9% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$14.7

84.9% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

14.87%

Pharma revenue growth rate

0.59%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.32%

Calculation

US$196.30m

Earnings '28

19.96x

PE Ratio '28

US$3.92b

Market Cap '28

US$3.92b

Market Cap '28

216.04m

No. shares '28

US$18.14

Share Price '28

US$18.14 Share Price '28

Discounted to 2025 @ 7.31% p.a.

US$14.68

Fair Value '25